Evidence map›Paper›PMID 42130792›Full record

ArticleClinical case reports2026

Pulmonary Aspergillosis Treated With Oral Amphotericin B (MAT2203) in a Patient With HIV-Related Cryptococcal Meningitis.

Enock Kagimu, Elizabeth Senkoro, Jane Gakuru, Morris K Rutakingirwa, David R Boulware, David B Meya, Richard Kwizera

Abstract read
In one paragraph

Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Enock KagimuInfectious Diseases Institute, College of Health Sciences Makerere University Kampala Uganda.ORCID https://orcid.org/0000-0002-0291-651X
Elizabeth SenkoroChronic Diseases Clinic of Ifakara Ifakara Health Institute Ifakara town Tanzania.
Jane GakuruInfectious Diseases Institute, College of Health Sciences Makerere University Kampala Uganda.
Morris K RutakingirwaInfectious Diseases Institute, College of Health Sciences Makerere University Kampala Uganda.ORCID https://orcid.org/0000-0003-2276-360X
David R BoulwareDivision of Infectious Diseases and International Medicine, Department of Medicine University of Minnesota Minneapolis Minnesota USA.
David B MeyaInfectious Diseases Institute, College of Health Sciences Makerere University Kampala Uganda.
Richard KwizeraInfectious Diseases Institute, College of Health Sciences Makerere University Kampala Uganda.ORCID https://orcid.org/0000-0002-5270-3539

Funding

NPGH LEADERs YR12: OBSSR (Greenberg, Ngwafong Mukere) & NIBIB (Lee)D43TW009345 · FIC · UNIVERSITY OF WASHINGTON · PI Dibyadyuti Datta, Chandy C. John · 2017 to 2026
$15.2M
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related MeningitisR01NS086312 · NINDS · UNIVERSITY OF MINNESOTA · PI David R Boulware, David Bisagaya Meya · 2013 to 2026
$8.3M
Determining the performance and accuracy of SILVAMP TB LAM and cost-effectiveness of diagnostic testing for TB meningitis.R01AI170158 · NIAID · UNIVERSITY OF MINNESOTA · PI Nathan Bahr · 2022 to 2026
$3.5M
TB Meningitis: Evaluating CSF Immunology to Discover Hidden Disease and Potential Immunomodulatory TherapiesR01AI162786 · NIAID · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, MEYA, DAVID BISAGAYA · 2021 to 2025
$3.3M
Encochleated Oral Amphotericin for Cryptococcal Meningitis TrialR01NS110519 · NINDS · UNIVERSITY OF MINNESOTA · PI BOULWARE, DAVID R, MEYA, DAVID BISAGAYA · 2019 to 2022
$2.6M
Minnesota-Makerere-Mbarara Neuro-Infectious Disease Research Training ConsortiumD43TW012266 · FIC · UNIVERSITY OF MINNESOTA · PI David R Boulware, David Bisagaya Meya · 2024 to 2026
$747k
Midcareer Mentoring for Clinical Research in HIV/AIDS-related cryptococcal and TB meningitisK24AI184270 · NIAID · UNIVERSITY OF MINNESOTA · PI David R Boulware · 2024 to 2026
$648k
FIC NIH HHS D43 TW009345FIC NIH HHS D43 TW012266NIAID NIH HHS K24 AI184270NIAID NIH HHS R01 AI162786NIAID NIH HHS R01 AI170158NINDS NIH HHS R01 NS086312NINDS NIH HHS R01 NS110519
6 · The paper itself

Abstract

The case highlights the need to consider aspergillosis in patients with cryptococcal infections and unexplained respiratory symptoms, as well as in smear-negative pulmonary tuberculosis. When standard triazoles are unavailable, novel oral amphotericin B (MAT2203) successfully treated both invasive pulmonary aspergillosis and cryptococcosis in this case of coinfection, warranting further evaluation.

Indexed as

amphotericin Bchronic pulmonary aspergillosiscryptococcal meningitisfungal infectionsHIVinvasive pulmonary aspergillosis

Identifiers

PMID42130792
PMCPMC13161983

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.